Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.60 |
| ▸ | HBB | P68871 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | POLG | P54098 | 2/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acyclovir SCHEMBL5930416 | 0.94 | PNP (0.65) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL8052815 | 0.89 | PNP (0.68) | PNPHBBBLMUSP2TSHR | |
| SCHEMBL16063240 | 0.84 | POLB (0.62) | PNPPOLGHPRT1POLBPOLA1 | |
| Acyclovir SCHEMBL543440 | 0.80 | PNP (0.91) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL145614 | 0.80 | PNP (0.91) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL23440044 | 0.80 | PNP (0.91) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL145606 | 0.80 | PNP (0.91) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL543439 | 0.79 | PNP (0.84) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL11310318 | 0.79 | PNP (0.88) | PNPHBBBLMUSP2TSHR | |
| Acyclovir SCHEMBL11310314 | 0.79 | PNP (0.88) | PNPHBBBLMUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | QUADEX PHARMACEUTICALS, LLC | 2006-06-22 | — | — | US | disclosed |
| US-6015573-A | TREATMENT OF RESISTANT HERPES VIRUS WITH NUCLEOSIDE PHOSPHATE ESTERS | RESOLUTION PERFORMANCE PRODUCTS LLC | 2000-01-18 | — | — | US | disclosed |
| US-5879700-A | TREATING HERPES VIRUS INFECTIONS | HOSTETLER KARL Y (US) | 1999-03-09 | — | — | US | disclosed |
| EP-0831794-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5756116-A | VIRICIDES USING ACYCLOVIR RESISTANT STRAIN OF HERPES VIRUS | HOSTETLER KARL Y (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0831794-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0746319-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996040088-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746319-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5580571-A | ACYCLOIR MONO OR DIPHOSPHATE; TOPICAL USE IN HERPES VIRUSINFECTIONS | HOSTETLER KARL Y (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | DCTD, ADA, TYMP | PNP 41/4885HBB 4845/4885BLM 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.